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Abstract  
Background: Rett syndrome is a pervasive neurological disorder with impaired gait as one 
criterion. This study investigated the capacity of three accelerometer-type devices to 
measure walking activity in Rett syndrome.  
Methods: Twenty-six participants (mean 18 years, SD 8) wore an Actigraph, ActivPAL and 
StepWatch Activity Monitor (SAM) during a video-taped session of activities. Agreement was 
determined between step-counts derived from each accelerometer and observation. 
Repeatability of SAM-derived step counts was determined using pairs of one-minute epochs 
during which the same participant was observed to walk with the same cadence. 
Results: The mean difference (limit of agreement) for the Actigraph, ActivPAL and SAM 
were 41 (SD 33), -16 (SD 21) and -1 (SD 16) steps/min, respectively. Agreement was 
influenced by a device/cadence interaction (p < 0.001) with greater under-recording at higher 
cadences. For SAM data, repeatability of step-count pairs was excellent (intraclass 
correlation coefficient 0.91, 95% CI 0.79-0.96). The standard error of measurement was 6 
steps/min and we would be 95% confident that a change ≥17 steps/min would be greater 
than within-subject measurement error. 
Conclusions: The capacity of the SAM to measure physical activity in Rett syndrome allows 
focus on participation-based activities in clinical practice and clinical trials. 
 
Introduction 
Rett syndrome is a rare neurological disorder usually caused by a mutation in the X-linked 
MECP2 gene [1]. Following largely normal early development, there is period of 
developmental regression with loss of hand and communication skills and development of 
hand stereotypies and impaired gait [2]. The resultant disability is severe with dependence 
for most activities of daily living [3] and co-morbidities such as epilepsy [4], poor growth [5] 
and scoliosis [6] may ensue. Nevertheless, using video data from individuals in the 
Australian Rett Syndrome Database (n = 99) we found that approximately 43% of girls and 
women were able to walk without assistance with a further 27% able to walk short distances 
with some assistance [7]. The ability to walk is in part related to the specific MECP2 
mutation [8] and may or may not decline with age [9]. 
 
Beyond the measurement of gross motor skill levels [7], measures of functional 
performance, such as step counts, can assist an understanding of the extent gross motor 
skills are used during daily life. There is growing knowledge and understanding of the 
biological basis for neurological disorders such as Rett syndrome [10] and clinical trials are 
planned to test therapeutics that hope to reverse some signs [11]. Therefore validated 
measures of physical activity, such as step counts, are important not only to monitor function 
during daily life but also to use as outcome measures in these new trials of pharmaceutical 
agents. 
 
Accelerometers measure the rate and magnitude of body movements and are able to 
calculate the intensity, frequency and duration of physical activity [12]. Models with variable 
levels of sophistication are available and there is potential to measure physical activity in 
persons with atypical walking patterns. For example, there is some validation of the 
Actigraph in children with cerebral palsy [13] and in those with acquired head injury [14]; the 
ActivPAL has been used to characterize activity in patients with Parkinson Disease [15]; and 
the StepWatch Activity Monitor™ (SAM) has produced accurate and reliable measures in 
the elderly [16], those with respiratory conditions who walk very slowly [17] and Alzheimer’s 
disease [18]. Each is worn at a different body location, steps are counted using different 
algorithms and their comparative application in Rett syndrome is not known. We were the 
first to collect initial data on the accuracy of the SAM in 12 girls and women with Rett 
syndrome [19]. Although the sample size was small and the SAM under-reported steps 
where gait was extremely slow [19], accuracy was promising in this sample which comprised 
participants with a range of gross motor skill levels.  
 
The population-based Australian Rett Syndrome Database (ARSD) was established in 1993 
and collects data longitudinally from families with a daughter affected by Rett syndrome [20]. 
Recruiting families from the ARSD, this study sought to expand our previous investigation 
and examine the capacity of three different accelerometer-type devices (Actigraph, ActivPAL 




Families from the ARSD [20] who lived in either Western Australia or Victoria in Australia 
were recruited if their daughter with Rett syndrome was able to walk independently or with 
assistance. Diagnosis of Rett syndrome was confirmed using diagnostic criteria [2] or the 




Three different accelerometer-type devices were used. The Actigraph™ GTX3 (ActiGraph, 
Pensacola, FL, USA) is a triaxial accelerometer with inclinometer that attaches to the waist 
using an elasticized belt and measures activity counts, vector magnitude and steps taken. 
The ActivPAL™ (PAL Technologies, Glasgow, UK) is a uniaxial accelerometer that attaches 
to the thigh using an adhesive pad. It has dual sensors including an inclinometer. This 
device detects thigh inclination and limb movement and provides information pertaining to 
the number of steps taken. It also separates time spent in supine and sitting from time in 
standing and walking. The SAM (OrthoCare Innovations, WA, USA) is an accelerometer-
type device that attaches to the ankle using a Velcro strap and responds to acceleration, 
position and timing. It measures the number of steps taken.  
 
Procedures and measures 
Each device was programmed using proprietary instructions. Thereafter each participant 
was fitted with all three devices and encouraged to undertake physical activities for 20 to 30 
minutes with supervision and assistance as necessary. Activities, which included walking at 
different speeds and on different terrains and inclines, were video-taped by an investigator. 
For the video-taped observations, a step was counted when the foot cleared the ground and 
moved in either a forward, sideways or backward direction. Two trained observers counted 
steps during each video session and mean values were used for analyses. 
 
General and complex gross motor skills were measured with the recently developed Gross 
Motor Scale for Rett syndrome [7]. The general gross motor skill subscale comprised 10 
items pertaining to tasks such as sitting, standing and walking as well as standing up from 
sitting. The maximum score is 40 with higher scores representing better general gross motor 
skills. The complex gross motor skills subscale comprised five items that were more 
complex in nature and include walking on a slope, stepping over an obstacle, bending down 
to touch the floor, standing up from the floor and running. The maximum score is 20 with 
higher scores representing better complex gross motor skills [7]. 
 
Ethics approval for this study was provided by the Human Research Ethics Committee at 
Curtin University, Western Australia and families provided written informed consent for their 




The numbers of steps observed on the video-tapes was the criterion measure. For each 
device, Bland-Altman analyses [21] were conducted to determine agreement (i.e. accuracy) 
between the average step count each minute derived from the video-tape and the average 
step count each minute, recorded by the device. Hierarchical random effects modelling was 
used to assess the influence of device type and cadence on agreement. The model used 
agreement in step count (device – video-tape) as the dependent variable with minute (within 
participant) as random effects and device type and cadence as fixed effect predictors. In 
addition, a model incorporating an interaction effect of accelerometer type with cadence was 
assessed to determine whether accuracy varied with cadence. 
 
Repeatability 
For the best performing device, repeatability was assessed using step counts recorded by 
the device over two separate one-minute epochs that were characterized by an identical 
number of video-taped steps. If there was more than one pair of minutes that met this 
criterion, the first pair was analyzed. Using these data, an intraclass correlation coefficient 
(ICC) was calculated. The standard error of measurement, defined as the square root of the 
mean square error term using repeated measures analysis of variance, was determined and 
then used to calculate the minimal detectable difference (SEM x √2 x 1.96) [22]. 
 




In December 2012, the ARSD included 392 girls and women born since 1976 of whom 64 
(16.3%) had died since its inception. Twenty-nine families were contacted regarding 
participation in the study and 28 provided consent giving a recruitment fraction of 96%. Two 
girls were unwell at the time of assessment and therefore 26 girls and women (mean age of 
18 years, SD 8) participated. Most of the common mutation categories were represented (C-
terminal [n=4], p.R294X [n=4], p.R133C [n=3], p.R270X [n=3], p.R168X [n=2], large deletion 
[n=2], p.R306C [n=1], p.T158M [n=1], p.R255X [n=1], p.R133H [n=1], other [n=1]). Three did 
not have a pathogenic mutation. Twenty-one (80.8%) were able to walk independently and 
five (19.2%) needed assistance. Scores on the general motor scale ranged from 15 to 40 
and on the complex motor scale ranged from 5 to 20. The mean duration of the video-taped 
session of activities was 12.1 minutes (SD 6.5) in duration and a total of 313 minutes of 
activity were available for analysis. All participants appeared comfortable wearing the three 
devices and no participant jogged or ran during the testing session.  
 
Agreement 
Bland-Altman plots showing agreement between the average steps/minute for each 
participant as observed in the video-tape with that derived from each of the devices are 
presented in figures 1, 2 and 3. The SAM was inadvertently not activated for one girl giving 
SAM data for 25 of the 26 girls and women. The mean difference (limit of agreement) for the 
Actigraph, ActivPAL and SAM were -41 (SD 33) steps/minute, -15 (SD 21) steps/minute and 
-1 (SD 16) steps/minute, respectively. 
 
  Insert figure 1, 2 and 3 about here 
 
The mean cadence for all video-taped minutes was 60 (SD 24) steps/minute. The random 
effects model confirmed that step counts derived using the SAM had the best agreement 
with the steps counted during the video-taped activities. Agreement varied by device (p < 
0.001) and compared to the SAM, on average the Actigraph under-recorded by 41 
steps/minute (95% confidence interval [CI], 39 to 43) and the ActivPAL under-recorded by 
15 steps/minute (95% CI, 13 to 17). Agreement was also influenced by cadence (p < 0.001) 
and an interaction effect between device and cadence (p < 0.001). All devices showed a 
tendency to under-record at high cadences with the Actigraph and ActivPAL under-recording 
also at slow cadences (figure 4). 
 
  Insert figure 4 about here 
 
Repeatability 
The video-tape analysis revealed that 20 participants took the same number of steps in at 
least two different one-minute epochs. Reliability of the step count pairs as measured by the 
SAM was strong (ICC 0.92, 95% CI 0.82 to 0.97). The standard error of measurement was 6 
steps/minute and the minimal detectable difference was 17 steps/minute, indicating that an 
observed difference using the SAM on the same individual of at least this magnitude would 
be necessary to be 95% confident that the difference was greater than measurement error.  
 
Discussion 
We have extended our previous assessment of the measurement properties of the SAM in 
Rett syndrome [19] to include a larger sample size and the testing of additional 
accelerometer-type devices. We chose to investigate these particular devices as preliminary 
data supporting their validity had been previously reported in persons with other neurological 
disorders [13-16,18]. Compared with steps counted during a video-tape of the assessment 
session, superior agreement was demonstrated between the steps derived using the SAM 
compared with the ActiGraph and the ActivPAL. This was true on average across the 
sample and over most cadences. Step counts measured via the SAM also demonstrated 
good repeatability in this population.  
 
The Actigraph showed the greatest differences from our observed video steps, particularly at 
higher cadences. Using earlier models of this device, moderately strong relationships 
between activity counts and observed activity were observed in children with cerebral palsy 
[13] and strong correlations between activity counts and self-reported physical activity were 
found in adults with multiple sclerosis [23]. Actigraph data correctly classified bouts of low 
and moderate physical activity but underestimated bouts of vigorous activity in adults with 
traumatic brain injury [14]. However, each of these studies examined similarities in 
measures using different devices rather than agreement with a gold standard measure 
which examines differences. More recently in the general population, the Actigraph GTX3 
which was used in the current study underestimated steps particularly during slower 
cadences (< 67m/min) compared with directly observed steps [24]. Our data also 
underestimated steps, in part due to slow cadences but also likely due to the abnormal gait 
patterns in our sample. Specifically, normal walking is characterized by a co-ordinated 
pattern of movement of the centre of gravity in horizontal, lateral and vertical planes [25]. 
The triaxial Actigraph records accelerations in all three planes and uses algorithms to then 
calculate step counts from the recorded acceleration episodes. Inspecting the raw data 
collected in our sample, we noted very few vertical displacements, indicating that vertical 
movements of the pelvis generally did not exceed the threshold for inclusion in the algorithm 
for identifying steps. These data nevertheless provide additional understanding of pelvic 
movement during gait in Rett syndrome and perhaps the Actigraph GTX3 provides a simple 
method of basic gait analysis in a clinical group for whom laboratory assessment is 
practically very difficult. Whilst the Actigraph is widely used in physical activity research in 
populations with largely normal gait patterns [26], at present, its utility in populations with a 
neurological disorder including Rett syndrome may be limited. 
 
We found that the ActivPAL also under-reported steps in Rett syndrome. Studies of healthy 
young participants have reported accurate measures of step counts during comfortable 
walking speeds across land [27] and during treadmill walking [28]. Nevertheless, accuracy 
has been compromised during free-living walking sessions [28] or at speeds slower than 40 
meters/minute [24]. In our sample, the ActivPAL under-recorded to a lesser extent than the 
Actigraph but agreement between step counts recorded using this device with the video-tape 
analysis was also compromised.  
 
Compared with the ActivPAL, the SAM has demonstrated similar [27] or superior [24] 
accuracy. In those with a chronic respiratory condition, the SAM was superior to the 
ActivPAL in identifying steps [17]. For those with gait affected by neurological impairments, 
the SAM had good accuracy in those with incomplete spinal injury [29] and Duchenne 
Muscular Dystrophy [30], and superior accuracy when compared with a Caltrac 
accelerometer [31] in patients with stroke. In our sample, the SAM recorded a similar step 
count to the observed during the video-analysis during the most commonly used cadences. 
Therefore, our data together with this earlier work suggests the SAM is currently the superior 
choice to measure walking activity in persons affected by a neurologic disorder. 
 
We also identified pairs of minutes during which the observed step count was identical and 
found the repeatability of the SAM step counts to be excellent. We calculated the SEM 
independently from ICC calculations [22] and for any individual, we are 95% confident that a 
change ≥ 17 steps/minute would be greater than measurement error. This threshold allows 
for the recording of additional fidgety or rocking movements that may not be steps but which 
would reflect natural test-to-test variability. During a bout of physical activity, an increase of 
at least 17 steps in a minute could be seen as important to identifying individual 
improvement and a feasible target when aiming to improve walking activity levels in Rett 
syndrome. 
 
Rett syndrome is a rare disorder with an incidence of 1 in 9,000 live female births [32]. The 
ARSD recruits from multiple sources throughout Australia and as such is population-based. 
We recruited families from two states of Australia to enable testing of an adequate sample 
size. Our participation fraction for the current study was high giving confidence that our 
sample of girls and women with walking skills was representative of the clinical population. 
Further, our sample demonstrated clinical variability in terms of age [33], mutation type [8] 
and gross motor skills [20] and therefore the results of this study pertain to the range of 
clinical characteristics seen in ambulant girls and women with Rett syndrome.  
 
Observation of videoed steps was our criterion measure but we acknowledge the potential 
for human error when identifying each step on the video. Nevertheless, we developed an 
operational definition for a step prior to the analysis of the video tapes and two observers 
independently counted the steps. We defined cadence as the number of steps in a minute 
but we also acknowledge that each minute likely included episodes at different speeds. The 
number of steps in a minute was our best estimate of cadence since those with Rett 
syndrome cannot walk at predetermined cadences because of cognitive impairment and 
dyspraxia [34]. For similar reasons, our study comprised assessment in natural “free-living” 
conditions rather than laboratory-based testing with a strict testing protocol, and therefore 
we cannot identify cut-points in constant cadences below or above which agreement would 
be unsatisfactory. However, “free-living” assessment enabled estimates of device accuracy 
in the conditions of use. In the general population, measurement properties of the Actigraph 
and ActivPAL have both been shown to record fewer steps than the SAM in “free-living” 
conditions [24]. We also acknowledge that the development of condition-specific algorithms 
for devices such as the Actigraph and ActivPAL may improve their application in persons 
with neurological impairments. 
 
In conclusion, our novel field observations enabled pragmatic assessment of how well three 
accelerometer-type devices could detect steps in Rett syndrome. Our data demonstrated 
that the SAM was the most accurate device and provides a platform for future analyses of 
whole day activity and sedentary behaviors. Repeatability of step counts recorded using the 
SAM was good suggesting that a small difference would be necessary to be confident of a 
change that exceeded measurement error. Over time, there have been shifting paradigms in 
the assessment and management of disability issues particularly in association with the 
introduction of the International Classification of Functioning Disability and Health [35]. That 
is, there is reduced focus on quantifying capacity or impairments and increased interest in 
quantifying participation in activities of daily life. Participation-based activities such as 
walking have potential to be critical influences on wellbeing and quality of life [36] and our 
study puts the spotlight firmly on walking-based activities and promotion of active lifestyles 
for this group. The capacity to collect accurate measures of physical activity in Rett 
syndrome enables additional monitoring of clinical progress and can contribute to rigorous 
evaluation of interventions such as cell-based molecular therapies in our new current era of 
clinical trials for rare disorders. 
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Average steps/min counted during video 
analysis 
Figure 4 
StepWatch Activity Monitor (SAM) 
ActivPAL 
Actigraph 
Implications for Rehabilitation 
 Many girls and women with Rett syndrome are able to walk on their own or 
with assistance but with altered movement patterns. 
 Validated measures of physical activity, such as step counts, have potential 
to monitor function during daily life.  
 Compared with other forms of accelerometer-type devices such as ActiGraph 
and ActivPAL, the StepWatch Activity Monitor (SAM) measured step counts 
with good accuracy and repeatability. 
 The capacity of the SAM to measure physical activity in Rett syndrome allows 
focus on participation-based activities in clinical practice and clinical trials. 
